Why is Medicamen Biotec falling/rising?

As of 08-Jul, Medicamen Biotech Ltd's stock price is currently at 402.15, reflecting a decrease of 0.6, or 0.15%. The stock has underperformed significantly over various periods, with a 1-week return of -4.03% and a year-to-date decline of -21.03%. Despite today's performance showing an outperformance against its sector by 0.78%, the stock is trading below all key moving averages, indicating a bearish trend. Additionally, the company has reported poor long-term growth, with an operating profit decline of -16.39% over the last five years, and its return on capital employed (ROCE) is at a low of 5.30%. The stock's valuation appears expensive compared to its peers, and it has consistently underperformed against the benchmark, generating a return of -15.70% over the past year.
In the broader market context, the Sensex has shown a slight increase of 0.02% over the past week, contrasting with Medicamen Biotech's significant decline. The stock's performance has lagged behind the benchmark, particularly over the last three years, where it has consistently underperformed, highlighting a trend of weakness relative to the market. The liquidity of the stock remains adequate, with a notable increase in delivery volume, suggesting some investor interest; however, the overall negative financial indicators and the company's low cash reserves continue to weigh heavily on its stock price.